As G6PD testing is usually unavailable in malaria endemic areas, the prescriber treating vivax or ovale malaria is currently faced with the therapeutic dilemma of either not giving the drug, and failing to prevent relapses with their attendant substantial morbidity, or giving it and causing iatrogenic haemolysis in G6PD-deficient patients. This evidence concerns the gene G6PD and malaria.